IEEE bulk retraction of 1,417 conference papers announced on 28 October, the largest single bulk retraction by any publisher. The papers were linked to paper-mill advertisements and represent less than 0.06% of conference publications over six years.
Key points
Announcement date: 28 October statement by IEEE in New York City.
Retraction count: 1,417 conference papers withdrawn in one batch.
Sources
PROGRESS trial transcatheter aortic-valve replacement reduces 2-year events
PROGRESS trial presented at TCT2026 shows transcatheter aortic-valve replacement lowered the 2-year composite of death or heart-failure events to 16.7% versus 23.9% with surveillance. Results are from patients with moderate aortic stenosis and high-risk features.
Key points
2-year death or heart-failure event rate: 16.7% with transcatheter aortic-valve replacement, 23.9% with surveillance.
Presented at #TCT2026.
Sources
- Original post
- nej.md - Linked in the post
MARRS enables up to 100% in vitro and 84% in vivo editing
MARRS is a multivalent ADAR1-recruiting RNA editing platform that achieves up to 100% adenosine-to-inosine editing in vitro and 84% in vivo. It uses engineered RNA aptamers targeting the Zα domain of ADAR1 p150 embedded in a circular RNA scaffold to recruit endogenous ADAR1.
Key points
Editing efficiency reaches 100% in cultured cells.
In mouse models, editing efficiency reaches 84% with high specificity.
Sources
Bispecific CCR8-CD3 antibody combats tumors
Bispecific CCR8-CD3 antibody depletes regulatory T cells and revives anti-tumor T cells, combating multiple tumor types in mice. It also potentiated immunotherapy in mice and was safe in large animals.
Key points
Target: CCR8 to deplete regulatory T cells
Safety: Safe in large animals
Sources
- Original post
- scim.ag - Linked in the post
ASPIRED trial: 14-day ECG monitoring no benefit
ASPIRED trial found immediate 14-day ECG monitoring did not reduce patient-reported syncope episodes at 1 year compared with standard care. The findings are detailed in the full trial summary.
Key points
Result: Immediate initiation of 14-day ECG monitoring did not result in significantly fewer patient-reported syncope episodes at 1 year than standard care.
Population: Patients with syncope that remained unexplained after evaluation in the ED.
Sources
- Original post
- nej.md - Linked in the post
JEEPERS tool announced for detecting and correcting jagged-end errors in cfDNA methylation
JEEPERS is a tool to detect and correct jagged-end-induced errors in cell-free DNA methylation analysis. It is introduced as a new capability for handling these specific errors.
Key points
Tool: JEEPERS detects jagged-end-induced errors in cfDNA methylation analysis.
Tool: JEEPERS corrects jagged-end-induced errors in cfDNA methylation analysis.
Sources
- Original post
- nature.com - Linked in the post